MOREPENLAB — Morepen Laboratories Balance Sheet
0.000.00%
- IN₹26.35bn
- IN₹26.66bn
- IN₹18.12bn
- 54
- 29
- 33
- 29
Annual balance sheet for Morepen Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 414 | 158 | 217 | 169 | 1,052 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 2,126 | 2,913 | 2,978 | 3,561 | 3,968 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 5,268 | 7,343 | 7,562 | 8,890 | 11,594 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,312 | 1,608 | 1,840 | 2,377 | 3,703 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 8,581 | 10,701 | 11,105 | 12,932 | 17,781 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,038 | 4,565 | 3,212 | 4,020 | 5,007 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4,334 | 4,915 | 3,576 | 4,460 | 6,219 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 4,247 | 5,786 | 7,529 | 8,472 | 11,562 |
| Total Liabilities & Shareholders' Equity | 8,581 | 10,701 | 11,105 | 12,932 | 17,781 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |